{"filings":[{"id":297004,"accession_number":"0001178913-23-002225","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemomab Therapeutics discloses CFO compensation: $260K salary, 45% bonus, 102,860 ADS options at $1.70","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $260,000 for new CFO Sigal Fattal, plus customary social benefits.","Yearly bonus potential of 45% of base salary, based on mutually agreed objectives subject to Compensation Committee approval.","Grant of options to purchase 102,860 American Depositary Shares at $1.70 per ADS, vesting over 4 years.","Options accelerate upon a change in control (CIC); exercise period extended to 12 months post-termination (except for Cause)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297003,"accession_number":"0001178913-23-002136","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2023-06-05T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab appoints Adi Mor CEO, Sigal Fattal CFO; extends cash runway to end of 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adi Mor, co-founder and CSO, reappointed CEO effective June 1, 2023, replacing Dale Pfost.","Sigal Fattal, VP Finance, reappointed CFO, replacing Donald Marvin, effective same date.","Nissim Darvish appointed Chairman of Board, replacing Pfost.","Cash runway extended to end of 2024 via cost reductions; Phase 2 SSc trial suspended to preserve capital.","On track for PSC Phase 2 topline data readout in latter part of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297002,"accession_number":"0001178913-23-001809","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemomab Q1 net loss $8.8M; cash $32.8M; CM-101 Phase 2 NASH trial meets safety endpoint","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.8M ($0.04 per share) vs $5.1M in Q1 2022; R&D expenses rose to $6.9M from $2.7M.","Cash, equivalents and short-term deposits $32.8M at March 31, 2023, down from $39.9M at Dec 31, 2022; runway extended through H1 2024.","CM-101 Phase 2 NASH liver fibrosis trial met primary safety endpoint; showed positive activity on fibrotic and inflammatory biomarkers.","FDA cleared IND for CM-101 Phase 2 systemic sclerosis trial; initial U.S. sites expected to open mid-2023.","Phase 2 PSC trial advancing with higher dose cohort; top-line data from double-blind portion expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317383,"accession_number":"0001178913-23-000679","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemomab receives FDA clearance to start Phase 2 trial of CM-101 in systemic sclerosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for Phase 2 ABATE trial of CM-101 in systemic sclerosis (SSc).","CM-101 is a first-in-class monoclonal antibody targeting CCL24; has Orphan Drug designation for SSc and PSC.","Trial to enroll 45 patients; primary endpoint safety; top-line data expected H2 2024.","CM-101 previously well-tolerated in early trials, reduced fibro-inflammatory biomarkers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317382,"accession_number":"0001178913-23-000670","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemomab reports FY2022 net loss of $27.6M; cash runway through March 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.6M in 2022 vs $12.5M in 2021; R&D expenses rose 168% to $17.0M.","Cash used in operations was $20.4M; cash, equivalents and deposits fund operations through March 31, 2024.","Phase 2 PSC trial actively recruiting; added 20mg/kg dose arm and open-label extension.","Phase 2 SSc trial planned for H1 2023; completed NASH trial met safety endpoint with encouraging biomarker activity.","No revenue from product sales; accumulated deficit of $64M at Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.121,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317381,"accession_number":"0001178913-23-000147","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemomab Therapeutics furnishes updated corporate presentation; no specific facts available from filing text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Chemomab Therapeutics filed an updated corporate presentation on January 11, 2023.","The presentation is intended for investor and analyst use; no financial results or material events were announced.","No further details from the presentation are included in the filing text provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317380,"accession_number":"0001178913-23-000010","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2023-01-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Chemomab CM-101 Phase 2a NASH trial meets safety endpoint; shows positive fibrosis biomarker activity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trial met primary endpoint: safety and tolerability; no significant injection site reactions, no anti-drug antibodies.","23 NASH patients (F1c-F3) received 8 SC doses of 5 mg/kg or placebo over 16 weeks.","CM-101 showed greater improvements vs placebo in fibrosis biomarkers ProC-3, ProC-4, ProC-18, TIMP-1, ELF.","Nearly 60% of CM-101 patients responded in ≥3 fibrosis biomarkers at week 20 vs 0% placebo.","Higher baseline CCL24 correlated with greater biomarker reductions; FibroScan liver stiffness improved vs placebo."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335606,"accession_number":"0001178913-22-004189","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K/A","filed_at":"2022-11-29T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Chemomab appoints Matthew Frankel as Chief Medical Officer & VP Drug Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Start Date November 14, 2022; report to Chairman & CEO Dale Pfost.","Annual base salary of $450,000; target performance bonus of 45% of base salary.","Special milestone bonuses: $100,000 after 60 days, $100,000 after 120 days.","Granted option to purchase 125,000 ADSs vesting over 4 years (25% annual, rest monthly).","Employment is at-will; governed by New York law with mandatory arbitration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335608,"accession_number":"0001178913-22-004061","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-11-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Israeli court approves Chemomab repurchase of 582,023 ADSs from co-founders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved repurchase of up to 582,023 ADSs for approx. $1,213,400 to help co-founders pay tax.","Tax liability stems from merger deferral that expires March 16, 2023.","Repurchase at market price to avoid bulk sales that could depress CMMB ADS price.","Company says cash runway unchanged, expected through end of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335607,"accession_number":"0001178913-22-004019","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-11-14T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab appoints Matthew Frankel as CMO & VP Drug Development, effective Nov 14","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Frankel will receive annual base salary of $450,000 and bonus potential of 45% of base.","He receives a signing bonus of $200,000, payable in two $100,000 installments within 60 and 120 days.","Granted options to purchase 125,000 ADRs, vesting over four years (25% on first anniversary, remainder monthly).","Frankel previously led clinical development at Boehringer Ingelheim, Novartis, Sandoz, and Reata Pharmaceuticals.","Interim CMO Dave Weiner will stay on as Senior Advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353046,"accession_number":"0001178913-22-003072","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemomab Q2 net loss $6.2M, cash $51.8M; NASH topline due by year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $6.2M ($0.03/share) for Q2 2022 vs $2.8M loss in Q2 2021; R&D expense rose to $2.9M from $1.3M.","Cash, equivalents and deposits $51.8M at June 30; runway expected through end of 2023.","Phase 2 NASH trial completed treatment; topline safety and activity data expected before year-end 2022.","Phase 2 PSC trial expanded to 93 patients across three dose cohorts; topline data anticipated H2 2024.","Appointed Jill Quigley to board, Ilan Vaknin as VP R&D, and Christina Crater as VP Clinical Development."],"consensus_eps_estimate":null,"consensus_eps_actual":0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370691,"accession_number":"0001178913-22-002410","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-06-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab appoints Jill M. Quigley to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jill M. Quigley appointed to Chemomab board and audit committee, effective June 16, 2022.","Quigley brings 20+ years biotech experience, including COO of Passage Bio and CEO of Nutrinia.","Board expands to seven directors; audit committee now includes Quigley as financial expert.","Quigley also serves on Terns Pharmaceuticals board (TERN) and chairs its audit committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370690,"accession_number":"0001178913-22-002314","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-06-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemomab reports 2022 Annual Meeting vote results; all proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 1: re-elect Dr. Nissim Darvish as Class I director received 84,055,680 FOR, 591,060 AGAINST.","Proposal 2: approve amendment to compensation of Dr. Adi Mor (CSO) passed with 83,840,260 FOR.","Proposal 4: reappoint Somekh Chaikin (KPMG) as auditor approved with 84,152,640 FOR.","Proposal 3 (equity grants to directors) was withdrawn prior to the meeting.","Total shares represented: 84,756,220 ordinary (37.16% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370689,"accession_number":"0001178913-22-002261","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-06-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemomab Director Joel Maryles to step down at 2022 AGM","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joel Maryles, Class I director, notified Chemomab on May 31, 2022 he will not seek re-election.","Departure effective at the 2022 Annual General Meeting on June 7, 2022.","Departure not due to any disagreement with the Company, management, board, or operations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370688,"accession_number":"0001178913-22-001896","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemomab Q1 net loss $5.1M; cash $57.5M; advancing CM-101 in PSC and SSc","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $5.1M ($0.02 per share) vs $1.7M in Q1 2021; R&D expenses $2.7M, G&A $2.6M (incl $0.9M stock comp).","Cash and equivalents $57.5M at March 31, 2022, down from $61.2M at Dec 31, 2021.","Completed enrollment in Phase 2 liver fibrosis study; interim PSC readout expected late 2022; SSc Phase 2 launch planned by year-end.","Appointed Jack Lawler as VP of Global Clinical Development Operations.","Presented CCL24 data at SSc congress; findings support CM-101's role in fibrosis and endothelial damage."],"consensus_eps_estimate":null,"consensus_eps_actual":0.022,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389754,"accession_number":"0001178913-22-001006","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemomab reports FY2021 net loss of $12.5M; revises CM-101 clinical program to extend cash runway through end 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.5M ($0.06 per share) in FY2021 vs $6.0M in FY2020; cash $61.2M at Dec 31, 2021.","Expanding Phase 2 PSC trial with dose-finding cohorts and open-label extension; interim analysis expected H2 2022.","Focusing SSc trial on earlier proof of concept; trial initiation anticipated H2 2022.","Winding down liver fibrosis subcutaneous formulation study; data readout targeted near end of 2022.","Cash runway extended ~6 months to end of 2023; company expects 3-4 data readouts over next 24 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389753,"accession_number":"0001178913-22-000575","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2022-02-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemomab shareholders approve CEO Dale Pfost as Chairman of the Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Special meeting on Feb 10, 2022; 89,749,560 shares represented (~39.35% of outstanding).","Shareholders voted to approve CEO Dr. Dale Pfost as Chairman of the Board.","Vote results: 84,227,920 FOR, 5,510,320 AGAINST, 11,320 ABSTAIN.","Requisite majority under Israeli Companies Law satisfied; non-controlling shareholder votes also approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407704,"accession_number":"0001178913-21-003880","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab CEO Dale Pfost expected to become chairman; Stephen Squinto resigns as chairman and director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stephen Squinto resigns as chairman and director effective Dec 19, 2021; decision not due to any disagreement with company.","CEO Dale Pfost, PhD expected to become chairman subject to shareholder vote in or around February 2022.","Planned succession; Squinto's term was set to lapse by June 2022; transition accelerated to Dec 2021.","Company advancing Phase 2 programs in primary sclerosing cholangitis, liver fibrosis; Phase 2 trial in systemic sclerosis planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407703,"accession_number":"0001178913-21-003771","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-12-03T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab CMO Aharon resigns; Weiner appointed Interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Arnon Aharon resigned as CMO effective Feb 1, 2022; will continue 60 days and as senior advisor.","Dr. David M. Weiner appointed Interim CMO effective immediately, part-time, based in U.S.","Dr. Weiner has 25+ years experience; previously CEO of Amathus Therapeutics, CMO at Lumos Pharma and aTyr Pharma.","Resignation not due to any disagreement with company or board.","Chemomab advancing CM-101 clinical programs in fibrotic/inflammatory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407702,"accession_number":"0001178913-21-003507","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemomab reports Q3 net loss of $3.0M; cash $64.3M; appoints new CEO and CFO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $64.3M as of Sept 30, 2021; expected to fund operations to mid-2023.","Net loss for Q3 2021 of $3.0M ($0.01/share) vs $1.2M loss in Q3 2020.","R&D expenses $1.5M (up from $1.0M); G&A $1.4M (up from $0.2M) due to public company costs and share-based comp.","Appointed Dale Pfost as CEO and Donald Marvin as CFO/COO; progressing three Phase 2 trials.","Phase 2 data readouts expected: liver fibrosis H1 2022, PSC H2 2022; SSc trial starts early 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.038,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407696,"accession_number":"0001178913-21-003512","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K/A","filed_at":"2021-11-12T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab appoints Donald Marvin as CFO & COO, replacing Sigal Fattal effective Nov 8, 2021","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sigal Fattal's engagement as interim CFO concluded by mutual agreement; she remains as senior consultant.","Donald Marvin named CFO, EVP & COO; base salary $460K, annual bonus target 45% of base.","Marvin receives 1.5% equity (4-yr vest) + up to 0.5% for strategic goals, $25K signing bonus.","Severance package of 12 months, increasing by 1 month every 2 years (max 18 months).","Marvin brings 35+ years experience; no family relationships or reportable transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407701,"accession_number":"0001178913-21-003475","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemomab Therapeutics files updated corporate presentation on November 10, 2021","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Filed Form 8-K on Nov 10, 2021, including Items 7.01 (Regulation FD) and 9.01 (Exhibits).","Attached updated corporate presentation as Exhibit 99.1, highlighting treatments for fibrotic diseases.","Company based in Kiryat Atidim, Tel Aviv, with ADS trading on Nasdaq under ticker CMMB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407700,"accession_number":"0001178913-21-003411","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab names Donald Marvin CFO, EVP & COO; outgoing interim CFO stays as advisor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald Marvin appointed CFO, EVP, and COO effective November 8, 2021.","Sigal Fattal's engagement as interim CFO concluded; she will serve as senior consultant to Marvin.","Marvin receives $460k base salary, 45% bonus potential, $25k signing bonus, and equity (1.5% + 0.5% performance) vesting over 4 years.","Marvin has over 35 years experience; previous roles include EVP/CFO at Lodo Therapeutics, Chairman/CEO at Concentric, co-founder of Orchid BioSciences.","CEO Dale Pfost cites Marvin's expertise in building life sciences companies through organic growth and strategic M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407699,"accession_number":"0001178913-21-003370","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemomab Therapeutics files updated corporate presentation on systemic sclerosis","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated November 3, 2021, focuses on systemic sclerosis (SSc) program.","No specific clinical data or financial results disclosed in the excerpt provided.","Live webinar held same day to discuss the updated presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407698,"accession_number":"0001178913-21-003253","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-10-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemomab shareholders approve CEO Dale Pfost employment terms at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Oct 25, 2021; 42.74% of outstanding shares represented.","Proposal to approve CEO Dr. Dale Pfost's employment terms passed with 96.3M for, 1.2M against.","Pfost was engaged as CEO on September 1, 2021.","Vote satisfied requisite majority under Israeli Companies Law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407697,"accession_number":"0001178913-21-003237","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-10-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemomab Therapeutics files updated corporate presentation for October 2021","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation covering its fibrotic disease pipeline.","Presentation date is October 2021; no specific financial or clinical data disclosed in the filing.","Presentation is furnished under Item 7.01 Regulation FD, not incorporated by reference.","No material changes to previously disclosed information are evident from the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426732,"accession_number":"0001178913-21-002894","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-09-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Chemomab appoints Dale Pfost as CEO; co-founder Adi Mor becomes CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Dale Pfost appointed CEO, subject to shareholder approval expected Q4 2021.","Dr. Adi Mor steps down as CEO, continues as Chief Scientific Officer and board member.","Pfost brings 35 yrs experience; served as CEO of six biotech firms, including public companies.","Pfost expected to join board and become Chairman in 2022 (subject to shareholder approval).","Company has two Phase 2 studies underway; third expected to start in coming months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426731,"accession_number":"0001178913-21-002694","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemomab Q2 net loss $2.8M; cash $67M; Phase 2 trials on track for 2022 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.8M ($0.01 per share) vs $1.1M loss in Q2 2020; R&D expenses $1.3M (up from $0.8M).","Cash and equivalents $67M at June 30, 2021, up from $58.2M at March 31; runway to mid 2023.","CM-101 Phase 2a SPRING (PSC) and SPLASH (liver fibrosis) enrolling; data expected in 1H/2H 2022.","Expanded partnership with AGC Biologics to manufacture CM-101 for pivotal studies and launch readiness.","Plan to initiate Phase 2 trial in Systemic Sclerosis in Q1 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.024,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426730,"accession_number":"0001178913-21-002338","cik":1534248,"company_name":"Chemomab Therapeutics Ltd.","ticker":"CMMB","form_type":"8-K","filed_at":"2021-07-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemomab Therapeutics Shareholders Approve Compensation, CEO Terms, Share Plan, and Auditor at 2021 Meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1: Compensation Policy approved with 103,259,980 votes for (99.5%), meeting Israeli Companies Law requirements for non-controlling shareholders.","Proposal 2: Amendment to CEO Dr. Adi Mor's engagement terms approved with 103,495,100 votes for (99.7%), satisfying requisite majority.","Proposal 3: Share incentive plan increase by 540,000 ADSs (10,800,000 ordinary shares) approved with 103,184,280 votes for.","Proposal 4: Reappointment of Somekh Chaikin (KPMG) as independent auditors approved with 103,862,300 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":13680717.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}